E. R. Walker, R. E. Mcgee, and B. G. Druss, Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis, JAMA Psychiatry, vol.72, pp.334-341, 2015.

S. Brown, Excess mortality of schizophrenia. A meta-analysis, Br J Psychiatry J Ment Sci, vol.171, pp.502-508, 1997.

P. Oakley, S. Kisely, and A. Baxter, Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: a systematic review and meta-analysis, J Psychiatr Res, vol.102, pp.245-253, 2018.

C. Hjorthøj, A. E. Stürup, and J. J. Mcgrath, Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis, Lancet Psychiatry, vol.4, pp.295-301, 2017.

B. G. Druss, R. M. Rohrbaugh, and C. M. Levinson, Integrated medical care for patients with serious psychiatric illness: a randomized trial, Arch Gen Psychiatry, vol.58, pp.861-868, 2001.

A. J. Mitchell and D. Lawrence, Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis, Br J Psychiatry J Ment Sci, vol.198, pp.434-441, 2011.

T. M. Laursen, T. Munk-olsen, and M. Vestergaard, Life expectancy and cardiovascular mortality in persons with schizophrenia, Curr Opin Psychiatry, vol.25, pp.83-88, 2012.

U. Hoang, M. J. Goldacre, and R. Stewart, Avoidable mortality in people with schizophrenia or bipolar disorder in England, Acta Psychiatr Scand, vol.127, pp.195-201, 2013.

I. Bitter, P. Czobor, and A. Borsi, Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study, Eur Psychiatry J Assoc Eur Psychiatr, vol.45, pp.97-103, 2017.

J. Westman, S. V. Eriksson, and M. Gissler, Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study, Epidemiol Psychiatr Sci, vol.2017, pp.1-9

C. Lemogne, H. Nabi, and M. Melchior, Mortality associated with depression as compared with other severe mental disorders: a 20-year follow-up study of the GAZEL cohort, J Psychiatr Res, vol.47, pp.851-857, 2013.

B. G. Druss and R. A. Rosenheck, Mental disorders and access to medical care in the United States, Am J Psychiatry, vol.155, pp.1775-1777, 1998.

O. Godin, D. Bennabi, and A. Yrondi, Prevalence of metabolic syndrome and associated factors in a cohort of individuals with treatment-resistant depression: results from the FACE-DR Study, J Clin Psychiatry, vol.80, 2019.

P. Gorczynski, J. Firth, and B. Stubbs, Are people with schizophrenia adherent to diabetes medication? A comparative meta-analysis, Psychiatry Res, vol.250, pp.17-24, 2017.

N. Sugawara, K. Maruo, and T. Sugai, Prevalence of underweight in patients with schizophrenia: a meta-analysis, Schizophr Res, vol.195, pp.67-73, 2018.

A. J. Mitchell and O. Lord, Do deficits in cardiac care influence high mortality rates in schizophrenia? A systematic review and pooled analysis, J Psychopharmacol Oxf Engl, vol.24, pp.69-80, 2010.

B. Stubbs, J. Williams, and F. Gaughran, How sedentary are people with psychosis? A systematic review and meta-analysis, Schizophr Res, vol.171, pp.103-109, 2016.

D. Vancampfort, S. Rosenbaum, and P. B. Ward, Exercise improves cardiorespiratory fitness in people with schizophrenia: a systematic review and meta-analysis, Schizophr Res, vol.169, pp.453-457, 2015.

E. Vera-garcia, F. Mayoral-cleries, and D. Vancampfort, A systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia: an update, Psychiatry Res, vol.229, pp.828-839, 2015.

M. Beary, R. Hodgson, and H. J. Wildgust, A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications, J Psychopharmacol Oxf Engl, vol.26, pp.52-61, 2012.

M. De-hert, J. Detraux, and R. Van-winkel, Metabolic and cardiovascular adverse effects associated with antipsychotic drugs, Nat Rev Endocrinol, vol.8, pp.114-126, 2011.

R. Doyle, D. O'keeffe, and A. Hannigan, The iHOPE-20 study: mortality in first episode psychosis-a 20-year follow-up of the Dublin first episode cohort, Soc Psychiatry Psychiatr Epidemiol, 2019.

T. Pillinger, K. Beck, and B. Stubbs, Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis, Br J Psychiatry J Ment Sci, vol.211, pp.339-349, 2017.

T. Pillinger, K. Beck, and C. Gobjila, Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis, JAMA Psychiatry, vol.74, pp.261-269, 2017.

P. Shah, Y. Iwata, and F. Caravaggio, Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis, Schizophr Res, vol.208, pp.420-429, 2019.

J. K. Patel, P. F. Buckley, and S. Woolson, Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study, Schizophr Res, vol.111, pp.9-16, 2009.

D. Cohen, O. Bonnot, and N. Bodeau, Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis, J Clin Psychopharmacol, vol.32, pp.309-316, 2012.

S. B. Teasdale, P. B. Ward, and R. Jarman, Is obesity in young people with psychosis a foregone conclusion? Markedly excessive energy intake is evident soon after antipsychotic initiation, Front Psychiatry 9, p.725, 2018.

A. J. Mitchell, D. Vancampfort, and A. D. Herdt, Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients, Schizophr Bull, vol.39, pp.295-305, 2013.

O. Lederman, S. Rosenbaum, and C. Maloney, Modifiable cardiometabolic risk factors in youth with at-risk mental states: a cross-sectional pilot study, Psychiatry Res, vol.257, pp.424-430, 2017.

M. Garaulet, F. B. Ortega, and J. R. Ruiz, Short sleep duration is associated with increased obesity markers in European adolescents: effect of physical activity and dietary habits. The HELENA study, Int J Obes, vol.35, pp.1308-1317, 2011.

D. Vancampfort, M. Wampers, and A. J. Mitchell, A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls, World Psychiatry, vol.12, pp.240-250, 2013.

R. Carney, J. Cotter, and T. Bradshaw, Cardiometabolic risk factors in young people at ultra-high risk for psychosis: a systematic review and meta-analysis, Schizophr Res, vol.170, pp.290-300, 2016.

J. Cordes, A. Bechdolf, and C. Engelke, Prevalence of metabolic syndrome in female and male patients at risk of psychosis, Schizophr Res, vol.181, pp.38-42, 2017.

R. E. Newberry, D. J. Dean, and M. D. Sayyah, What prevents youth at clinical high risk for psychosis from engaging in physical activity? An examination of the barriers to physical activity, Schizophr Res, vol.201, pp.400-405, 2018.

N. Manzanares, R. Monseny, and L. Ortega, Unhealthy lifestyle in early psychoses: the role of life stress and the hypothalamic-pituitary-adrenal axis, Psychoneuroendocrinology, vol.39, pp.1-10, 2014.

R. Carney, T. Bradshaw, and A. R. Yung, Monitoring of physical health in services for young people at ultra-high risk of psychosis, Early Interv Psychiatry, vol.12, pp.153-159, 2018.

J. Vermeulen, G. Van-rooijen, and P. Doedens, Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis, Psychol Med, vol.47, pp.2217-2228, 2017.

M. Huhn, A. Nikolakopoulou, and J. Schneider-thoma, Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis, Lancet Lond Engl, issue.11, 2019.

D. Siskind and S. Kisely, Balancing body and mind: selecting the optimal antipsychotic, Lancet Lond Engl, vol.394, pp.900-902, 2019.

L. Malandain, F. Thibaut, and L. Grimaldi-bensouda, Correlates and predictors of antipsychotic drug polypharmacy in real-life settings: Results from a nationwide cohort study, Schizophr Res, 2017.

F. Misawa, K. Shimizu, and Y. Fujii, Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects? A cross-sectional study, BMC Psychiatry, vol.11, p.118, 2011.

S. Ijaz, B. Bolea, and S. Davies, Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews, BMC Psychiatry, vol.18, p.275, 2018.

J. Tiihonen, E. Mittendorfer-rutz, and M. Torniainen, Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study, Am J Psychiatry, vol.173, pp.600-606, 2016.

P. Ellul, R. Delorme, and S. Cortese, Metformin for weight gain associated with second-generation antipsychotics in children and adolescents: a systematic review and meta-analysis, CNS Drugs, vol.32, pp.1103-1112, 2018.

D. J. Siskind, J. Leung, and A. W. Russell, Metformin for clozapine associated obesity: a systematic review and meta-analysis, PloS One, vol.11, p.156208, 2016.

W. Zheng, Q. Zhang, and D. Cai, Combination of metformin and lifestyle intervention for antipsychotic-related weight gain: a meta-analysis of randomized controlled trials, Pharmacopsychiatry, vol.52, pp.24-31, 2019.

C. Smith, H. Myles, and C. Galletly, Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk, Australas Psychiatry Bull R Aust N Z Coll Psychiatr, vol.25, pp.387-390, 2017.

J. Curtis, A. Watkins, and S. Rosenbaum, Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis, Early Interv Psychiatry, issue.1, 2016.

S. B. Teasdale, J. Curtis, and P. B. Ward, The effectiveness of the keeping the body in Mind Xtend pilot lifestyle program on dietary intake in first-episode psychosis: two-year outcomes, Obes Res Clin Pract, vol.13, pp.214-216, 2019.

M. E. Carey, J. Barnett, and Y. Doherty, Reducing weight gain in people with schizophrenia, schizoaffective disorder, and first episode psychosis: describing the process of developing the STructured lifestyle Education for People With SchizophrEnia (STEPWISE) intervention, p.186, 2018.

J. Deenik, D. E. Tenback, and E. C. Tak, Changes in physical and psychiatric health after a multidisciplinary lifestyle enhancing treatment for inpatients with severe mental illness: the MULTI study I, Schizophr Res, 2018.

J. Firth, R. Carney, and R. Elliott, Exercise as an intervention for first-episode psychosis: a feasibility study, Early Interv Psychiatry, vol.12, pp.307-315, 2018.

A. Baki, V. Brazzini-poisson, and F. Marois, Effects of aerobic interval training on metabolic complications and cardiorespiratory fitness in young adults with psychotic disorders: a pilot study, Schizophr Res, vol.149, pp.112-115, 2013.

E. Tumiel, A. Wichniak, and M. Jarema, Nonpharmacological interventions for the treatment of cardiometabolic risk factors in people with schizophrenia-a systematic review, Front Psychiatry, vol.10, p.566, 2019.

N. A. Rashid, M. Nurjono, and J. Lee, Clinical determinants of physical activity and sedentary behaviour in individuals with schizophrenia, Asian J Psychiatry, vol.46, pp.62-67, 2019.

B. Malinowski, K. Zalewska, and A. W?sierska, Intermittent fasting in cardiovascular disorders-an overview, Nutrients, vol.11, 2019.

R. De-cabo and M. P. Mattson, Effects of intermittent fasting on health, aging, and disease, N Engl J Med, vol.381, pp.2541-2551, 2019.

A. S. Abdelhamid, T. J. Brown, and J. S. Brainard, Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease, Cochrane Database Syst Rev, vol.7, p.3177, 2018.

D. L. Bhatt, P. G. Steg, and M. Miller, Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia, N Engl J Med, vol.380, pp.11-22, 2019.

G. P. Amminger, M. R. Schäfer, and K. Papageorgiou, Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial, Arch Gen Psychiatry, vol.67, pp.146-154, 2010.

R. J. Deckelbaum and P. C. Calder, Editorial: is it time to separate EPA from DHA when using omega-3 fatty acids to protect heart and brain?, Curr Opin Clin Nutr Metab Care, vol.23, pp.65-67, 2020.

M. Barbarawi, B. Kheiri, and Y. Zayed, Vitamin D supplementation and cardiovascular disease risks in more than 83,000 individuals in 21 randomized clinical trials: a meta-analysis, JAMA Cardiol, 2019.

P. V. Dludla, S. C. Dias, and N. Obonye, A Systematic review on the protective effect of N-acetyl cysteine against diabetes-associated cardiovascular complications, Am J Cardiovasc Drugs Drugs Devices Interv, vol.18, pp.283-298, 2018.

, What is HeAL. iphys, 2019.

, Algorithm and adaptations. iphys, issue.3, 2019.

C. Dornquast, J. Tomzik, and T. Reinhold, To what extent are psychiatrists aware of the comorbid somatic illnesses of their patients with serious mental illnesses? -a cross-sectional secondary data analysis, BMC Health Serv Res, vol.17, p.162, 2017.

C. Arbus, J. Clement, and T. Bougerol, Health management of older persons with chronically medicated psychotic disorders: the results of a survey in France, Int Psychogeriatr, vol.24, pp.496-502, 2012.

, ANSM : Agence nationale de sécurité du médicament et des produits de santé, p.17, 2019.

M. A. Graber, G. Bergus, and J. D. Dawson, Effect of a patient's psychiatric history on physicians' estimation of probability of disease, J Gen Intern Med, vol.15, pp.204-206, 2000.

E. Björk-brämberg, J. Torgerson, and A. N. Kjellström, Access to primary and specialized somatic health care for persons with severe mental illness: a qualitative study of perceived barriers and facilitators in Swedish health care, BMC Fam Pract, vol.19, 2018.

, ALD n o 23 -Schizophrénies. Haute Autorité de Santé, p.17, 2019.

B. Chaumette, O. Kebir, and C. Mam-lam-fook, Stress and psychotic transition: a literature review, L'Encephale, vol.42, pp.367-373, 2016.

O. Kebir, B. Chaumette, and F. Rivollier, Methylomic changes during conversion to psychosis, Mol Psychiatry, 2016.

T. Pillinger, E. Ambrosio, and R. Mccutcheon, Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and Queries and Answers Query: Merci de vérifier que les prénoms et les noms ont été correctement identifiés, Answer: oui Query: Nous avons traité la Fig. 3 en Tableau 3 et les figures et tableaux ont été renumérotés. Merci de valider. Answer: oui je valide Query: Merci de nous transmettre la déclaration de liens d'intérêts désormais obligatoire

, Query: Merci de compléter la référence [10] en nous fournissant les éléments manquants

, Answer: Increased Cardiovascular Mortality in People With Schizophrenia: A 24-year National Register Study J Westman 1 , S V Eriksson 2 , M Gissler 1, J Hällgren, vol.1

S. Epidemiol-psychiatr, Mol Psychiatry, vol.27, issue.5, pp.776-794, 2017.

J. Firth, N. Siddiqi, and A. Koyanagi, The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness, Lancet Psychiatry, vol.6, pp.675-712, 2019.

, Consensus statements, 2019.